Cite this asGuo T, Yuan X, Liu DF, Peng SH, Xu AM (2019) Long non-coding RNA HOXA11-AS facilitates cell migration and invasion by regulating microRNA-148a/WNT1 axis in gastric cancer. Arch Clin Gastroenterol 5(2): 019-026. DOI: 10.17352/2455-2283.000063
Recently, long non-coding RNAs (lncRNAs) have emerged as crucial players in the initiation and progression of multiple cancers including gastric cancer (GC). LncRNA HOXA11 antisense RNA (HOXA11-AS) has been found to be an oncogenic factor in GC. However, the molecular mechanisms responsible for these oncogenic properties have not been thoroughly elucidated. In the present study, the abundances of HOXA11-AS, miR-148a and WNT1 in GC tissues and cell lines were examined by qRT-PCR. Kaplan-Meier survival analysis was conducted to explore the relationship between HOXA11-AS expression and GC patient prognosis. Transwell assay was performed to evaluate cell migratory and invasive capacities. Bioinformatics, dual-luciferase reporter, RNA immunoprecipitation (RIP), and RNA-pull down assays were employed to analyze the interaction between miR-148a and HOXA11-AS or WNT1. Tumor xenograft experiments were performed to further examine the influence of HOXA11-AS knockdown on GC tumorigenesis in vivo. The protein levels of WNT1 and β-catenin were assessed by western bolt assay. We found that HOXA11-AS and WNT1 expression was upregulated, while miR-148a expression was downregulated in GC tissues and cell lines. HOXA11-AS expression was associated with tumor size, lymph node metastasis, TNM stage, and overall survival in GC. HOXA11-AS promoted migration and invasion of GC cells through downregulating miR-148a. And, miR-148a inactivated WNT1/β-catenin signaling pathway via directly targeting WNT1. Moreover, HOXA11-AS induced the activation of WNT1/β-catenin pathway, which was abrogated by miR-148a overexpression in GC cells. Additionally, HOXA11-AS knockdown suppressed the growth of GC xenograft tumors by upregulating miR-148 and inactivating WNT1/β-catenin signaling pathway in vivo. These results suggest that HOXA11-AS overexpression promoted the tumorigenesis and progression of GC through activating WNT1/β-catenin pathway via repressing miR-148a, providing a prospective therapeutic target for GC.
Gastric cancer (GC) is a serious public-health issue worldwide, ranking the first in gastrointestinal cancer-related morbidity and mortality . An estimated 26240 new cases and 10800 deaths from GC occurred in 2018 in the United States alone . Despite the great advances in the management of GC, the prognosis remains dismal, especially for individuals diagnosed with advanced disease [3,4]. Cell migration and invasion are considered to be the major events that can drive cancer progression . And, an in-depth understanding on the molecular basis involved in aggressive behaviors of GC contributes to the identification and development of novel biomarkers or therapeutic targets.
LncRNAs are a group of transcripts larger than 200 nucleotides that can regulate various cellular processes, such as cell proliferation, apoptosis, invasion, and migration [6,7]. Moreover, lncRNAs are closely associated with the occurrence and development of various cancers including GC [8,9]. LncRNA homeobox A11 antisense (HOXA11-AS), a highly conserved transcript, is located near the homeobox A11 (HOXA11) gene. And, Li et al. pointed out that abnormal expression of HOXA11-AS was associated with tumor aggressiveness and poor clinical outcomes in multiple cancers . Wang et al. revealed that HOXA11-AS expression was associated with glioma grade and poor prognosis, and HOXA11-AS overexpression promoted glioma tumorigenesis by regulating cell cycle progression . Moreover, it is worth noting that HOXA11-AS level exhibits a significant elevation in GC . However, the roles and detail mechanisms of HOXA11-AS involved in GC tumorigenesis and progression remain unclear.
A hypothesis suggests that lncRNAs can function as competing endogenous RNAs (ceRNAs) of miRNAs to regulate the expression of cancer-related target mRNAs . In the present study, we performed a series of experiments to investigate the roles of HOXA11-AS in GC as well as its potential molecular mechanisms. Results showed that HOXA11-AS expression was significantly upregulated in GC tissues and cell lines, and associated with the poor clinical outcome in GC. Besides, enforced expression of HOXA11-AS facilitated cell migration and invasion by miR-544a/WNT1/β-catenin pathway. Our study provided a novel ceRNA network in GC and a potential biomarker or therapeutic target for GC management.
Patients and tissue specimens: Our study was performed with the approval of the Research Ethics Committee of The First Affiliated Hospital of Anhui Medical University and all participants signed written informed consent prior to this research. Fresh tumor tissues and matching adjacent noncancerous tissues were collected from 30 GC patients underwent surgical resection between March 2010 and February 2012. All excised tissues were immediately frozen in liquid nitrogen and stored at -80°C. The clinicopathological parameters of GC patients, containing age, gender, tumor size, lymph node metastasis, and TNM stage, were summarized and shown as table 1.
All patients were followed-up and their survival patterns were monitored. Those who died from other diseases rather than GC were left out from the study. Patients diagnosed with GC were divided into high HOXA11-AS expression group (17 cases) and low HOXA11-AS expression group (13 cases). The overall survival patterns of GC patients were analyzed according to the difference of HOXA11-AS expression in tumor tissue samples.
Cell culture and transfection: Human gastric epithelial cell line GES-1 was obtained from American type culture collection (ATCC, Manassas, VA, USA). Human embryonic kidney cell line 293Tand gastric cancer cell lines SGC-7901 and MGC-803 were purchased from the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). All cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS, Gibco), and 1% penicillin/streptomycin (Solarbio, Beijing, China) at 37°C in a humidified air of 5% CO2.
The full-length fragments of HOXA11-AS were inserted into pcDNA3.1 vector to generate HOXA11-AS-overexpression plasmid (HOXA11-AS), with pcDNA3.1 vector as a negative control (vector). Small interfering RNA (siRNA) against HOXA11-AS (si-HOXA11-AS) and its control (si-NC), miR-148a mimic (miR-148a) and its negative control (miR-NC), miR-148a inhibitor (anti-148a) and its corresponding control (anti-NC) were purchased from Genepharma (Shanghai, China). SGC-7901 and MGC-803 cells were seeded into 6-well plates with a density of 1 × 105 cells/well, followed by the transfection of above products using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
RNA extraction and quantitative real-time PCR (qRT-PCR): Total RNA was isolated from GC specimens or cultured cells using Trizol reagent (Thermo Fisher, Wilmington, DE, USA) and miRNA was extracted using mirVanaTM miRNA Isolation Kit (Thermo Fisher) referring to the manufacturer’s procedures. First-strand cDNA was synthesized using High Capacity Reverse Transcription System Kit (Takara, Dalian, China). The reverse transcription primer sequences for miR-148a were 5’-GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA CAA G-3’. Then, qPCR reaction was conducted using Universal SYBR Green PCR Kit (Takara) on an ABI 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Results were calculated by 2-ΔΔCt method. GAPDH functioned as the housekeeping gene to normalize the expression of HOXA11-AS and WNT1. U6 small nuclear RNA (snRNA) served as the internal control to normalize miR-148a expression. qPCR primer sequences were displayed as below: HOXA11-AS (Forward, 5’-GAG TTT GAA GCC GTG GAT GT-3’; Reverse, 5’-AGA TGA GGG GAG AGG TGG AT-3’); WNT1 (Forward, 5’-TGC ACG CAC ACG CGC GTA CTG CAC-3’; Reverse, 5’-CAG GAT GGC AAG AGG GTT CAT G-3’); GAPDH (Forward, 5’-TAT GAT GAT ATC AAG AGG GTA GT-3’; Reverse, 5’-TGT ATC CAA ACT CAT TGT CAT AC-3’). miR-148a (Forward, 5’-GTG CAG GGT CCG AGG T-3’; Reverse, 5’-GCG TCA GTG CAC TAC AGA ACT T-3’), U6 (Forward, 5’-CTC GCT TCG GCA GCA CA -3’; Reverse, 5’-AAC GCT TCA GGA ATT TGC GT-3’)
Transwell assay: Cell migratory and invasive abilities were evaluated using Tanswell chambers (BD Biosciences, San Jose, CA, USA) in 24-well plates. For migration assay, SGC-7901 and MGC-803 cells maintained in serum-free medium were added into the upper chambers, and the bottom chamber was filled with complete medium containing 10% FBS. After 16h of incubation, cells on the basal side of the membranes were fixed, stained with hematoxylin (Sigma, St. Louis, MO, USA), and counted in three random fields under a microscope (Olympus, Tokyo, Japan). For invasion assay, the experimental procedures were performed as described above besides the pre-coating of the upper chambers with matrigel (BD Biosciences).
Dual-luciferase assay: The sites of HOXA11-AS targeting miR-148a or miR-148a targeting WNT1 were predicted by miRcode or TargetScan software, respectively. Partial sequences of HOXA11-AS or WNT1 3′-UTR containing miR-148a binding sites were inserted into the psiCHECK-2 vector (Promega, Madison, WI, USA) to generate wild-type HOXA11-AS (HOXA11-AS-WT) or WNT1 (WNT1-WT) reporter. Also, KOD-plus-mutagenesis kit (Toyobo, Osaka, Japan) was employed to generate the mutant HOXA11-AS (HOXA11-AS-MUT) or WNT1 (WNT1-MUT) reporter by mutating the nucleotides complementary to miR-148a. Luciferase reporter was transfected into 293Tcells along with miR-148a or miR-NC. At 48 h after transfection, luciferase activities were determined using a Dual-Luciferase Assay Kit (GeneCopoeia, Rockville, MD, USA).
RNA immunoprecipitation (RIP): RIP assay was carried out using the Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA, USA) according to manufacturer’s instructions. In brief, SGC-7901 cell lysates were incubated with protein A/G magnetic beads conjugated with anti-Argonaute2 (anti-Ago2, Abcam, Cambridge, MA, USA) or anti-IgG (Abcam). After 24 h of incubation, the beads were treated with proteinase K to remove the proteins and HOXA11-AS level in immunoprecipitation complex was detected by qRT-PCR assay.
RNA pull-down:RNA-pull down assay was performed to detect the interaction between HOXA11-AS and miR-148a. In brief, SGC-7901 cells were transfected with biotin-labeled miR-148a-WT (Bio-miR-148a-WT) or miR-148a-MUT (Bio-miR-148a-MUT) for 48h. Then, cell lysates were incubated overnight at 4°C with Streptavidin-Dyna beads (Invitrogen). Next, RNA was isolated from beads and HOXA11-AS level was determined by RT-qPCR assay.
Western blot assay: SGC-7901 and MGC-803 cells were prepared with RIPA lysis buffer (Thermo Fisher) supplemented with protease inhibitor (Thermo Fisher), followed by high-speed centrifugation to remove cell debris and insoluble substance. Then, protein concentration was determined using a Pierce BCA Protein Assay Kit (Thermo Fisher). Equal amounts of proteins were separated by SDS-PAGE and electrotransferred to PVDF membranes (Millipore). Next, the membranes were blocked overnight at 4°C with 5% non-fat milk, incubated for 2 h with primary antibodies against β-catenin and WNT1 at 37°C. After washing, the membranes were probed with horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling Technology, Inc., Danvers, MA, USA) for another 1.5 h. Finally, protein bands were visualized using a ECL kit (Biorbyt, Shanghai, China) on Bio-Rad ChemiDoc MP imaging system (Bio-Rad Laboratories, Hercules, CA, USA).
Tumor xenograft experiment: Male BALB/c nude mice (6-week-old) were purchased from Charles river (Beijing, China) and fed under a standard condition for one-week. SGC-7901 cells (2×106) infected with sh-NC or sh-HOXA11-AS lentiviruses (Hanbio Biotechnology Co., Ltd., Shanghai, China) were subcutaneously inoculated into the back of BALB/c nude mice. Tumor volume was measured every week and calculated using the following formula: volume = (length × width2)/2. At four weeks after injection, mice were sacrificed, and tumors were resected and weighed. All in vivo experiments were carried out with the national Guidelines of Animal Care and Use and the approval of Animal Research Ethics Committee of the First Affiliated Hospital of Anhui Medical University.
Statistical analysis: All data were analyzed through SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA). Data from more than 3 independent experiments were exhibited as the mean ± standard deviation (SD). Statistical difference between two groups was assessed by Student’s t-test. Difference analysis of multiple data was performed by one-way ANOVA, followed by Student-Newman-Keuls-q (SNK-q) test. P values less than 0.05 was identified as statistically significant.
HOXA11-AS expression was upregulated and associated with poor prognosis in GC: The level of wild type HOXA11-AS in GC tissues and adjacent normal tissues was firstly detected by qRT-PCR. Results showed that wild type HOXA11-AS level was strikingly upregulated in 30 GC tissues than that in adjacent normal tissues (Figure 1A). Afterwards, we further explored the correlation of HOXA11-AS expression and multiple clinicopathological parameters. Results presented that HOXA11-AS expression in GC tissues was not associated with age and gender of GC patients (Table 1, P>0.05), but was related with tumor size, lymph node metastasis and TNM stage (Table 1, P<0.05). Also, Kapan-Meier survival analysis revealed that patients with high HOXA11-AS expression had a poor overall survival compared with low HOXA11-AS expression group (Figure 1B). Also, a notable upregulation of HOXA11-AS level was observed in SGC-7901 and MGC-803 cells compared with GES-1 cells (Figure 1C). These results suggested that HOXA11-AS expression was upregulated and associated with poor prognosis in GC.
HOXA11-AS contributed to cell migration and invasion in GC: To further explore the effects of HOXA11-AS on GC progression, HOXA11-AS overexpression plasmid (HOXA11-AS) and siRNA (si-HOXA11-AS) were constructed and synthesized. Following transfection efficiency analysis disclosed that the transfection of HOXA11-AS overexpression plasmid effectively elevated HOXA11-AS expression in SGC-7901 cells, while si-HOXA11-AS introduction markedly reduced HOXA11-AS expression in MGC-803 cells (Figure 2A,B). Transwell assay showed that HOXA11-AS overexpression notably promoted SGC-7901 cell migration and invasion (Figure 2C,E), and HOXA11-AS knockdown markedly suppressed MGC-803 cell migration and invasion (Figure 2D,F).
Bioinformatics prediction analysis by miRcode website presents that there exists some complementary sequences between HOXA11-AS and miR-148a (Figure 3A). Following dual-luciferase reporter assay demonstrated that miR-148a overexpression resulted in the obvious reduction of luciferase activity of HOXA11-AS-WT reporter in 293Tcells, but had no much impact on luciferase activity of HOXA11-AS-MUT reporter (Figure 3B), suggesting that HOXA11-AS could bind with miR-148a through putative binding sites. RIP assay further disclosed that HOXA11-AS could be copiously enriched by Ago2 antibody rather than IgG antibody in SGC-7901 cells (Figure 3C), indicating that HOXA11-AS had the potential to interact with miR-148a in space. However, there are other miRNAs that may be targeted by HOXA11-AS, not only miR-148a. RNA pull-down assay followed by RIP is a powerful tool to confirm the specific interaction between miRNA and lncRNA . The results of RNA pull-down assay showed that the transfection of Bio-miR-148a-WT could induce the considerable enrichment of HOXA11-AS level in SGC-7901 cells compared with Bio-NC group, while the introduction of Bio-miR-148a-MUT had no much influence on HOXA11-AS level relative to Bio-NC group (Figure 3D). In a word, these data unveiled that HOXA11-AS could bind with miR-148a by predicted binding sites.
HOXA11-AS modulated cell migration and invasion through miR-148a: Subsequent qRT-PCR revealed that miR-148a expression was significantly downregulated in GC tissues (n=30) and cells compared with their counterparts (Figure 4A,B). And, miR-148a expression was remarkably reduced in HOXA11-AS-overexpressed SGC-7901 cells, but was dramatically increased in HOXA11-AS-depleted MGC-803 cells (Figure 4C,D), suggesting that HOXA11-AS could negatively regulate miR-148a expression in GC cells. Next, rescue experiments were performed to investigate whether the effects of HOXA11-AS on GC cell migration and invasion were mediated by miR-148a. Results showed that miR-148a overexpression suppressed the elevation of cell migratory and invasive capacities induced by HOXA11-AS in SGC-7901 cells (Figure 4E,G). And, miR-148a knockdown reversed the detrimental effects of HOXA11-AS loss on cell migration and invasion in MGC-803 cells (Figure 4F,H). Taken together, HOXA11-AS contributed to cell migration and invasion through downregulating miR-148a in GC.
WNT1 was an authentic target for miR-148a: Next, TargetScan online website was used to seek for potential targets of miR-148a. Among these candidate targets, WNT1 was selected because of its oncogenic role in GC as previously reported  (Figure 5A). To further confirm the interaction between miR-148a and WNT1, WNT1-WT and WNT1-MUT reporters containing wild-type or mutant miR-148a binding sites were constructed. Subsequent luciferase reporter assay showed that the luciferase activity of WNT1-WT reporter was dramatically reduced in miR-148a-overexpressed 293Tcells compared with miR-NC group (Figure 5B). However, miR-148a overexpression or not had no much impact on luciferase activity of WNT1-MUT reporter (Figure 5B). That was to say, miR-148a could interact with WNT1 3’UTR by predicted sites. Next, we found that WNT1 expression was notably upregulated in GC tissues and cell lines relative to corresponding negative controls (Figure 5C,D). Also, RT-qPCR assay demonstrated that miR-148a level was markedly elevated in SGC-7901 cells transfected with miR-148a mimic, but was remarkably downregulated in MGC-803 cells transfected with anti-miR-148a (Figure 5E). And, protein levels of WNT1 and β-catenin were strikingly reduced in miR-148a-overexpressed SGC-7901 cells, but was noticeably increased in miR-148a-silenced MGC-803 cells (Figure 5F), suggesting that miR-148a inactivated WNT1/β-catenin pathway via targeting WNT1.
HOXA11-AS activated WNT1/β-catenin pathway through repressing miR-148a: Next, Rescue experiments were performed to explore whether HOXA11-AS could regulate WNT1/β-catenin pathway through sponging miR-148a. Results showed that upregulation of HOXA11-AS stimulated WNT1 and β-catenin expression, while these effects of HOXA11-AS were weakened by miR-148a overexpression in SGC-7901 cells (Figure 6A). And, miR-148a loss alleviated the inhibitory effects of HOXA11-AS knockdown on WNT1 and β-catenin expression (Figure 6B). These results indicated that HOXA11-AS activated WNT1/β-catenin pathway through downregulating miR-148a.
HOXA11-AS knockdown inhibited GC xenograft tumor growth via the regulation of miR-148a/WNT1/β-catenin pathway in vivo.
Subsequent in vivo experiments presented that HOXA11-AS knockdown resulted in the remarkable reduction of GC xenograft tumor volume (Figure 7A) and weight (Figure 7B), suggesting that HOXA11-AS loss hindered GC tumorigenesis in vivo. Next, qRT-PCR assay validated that HOXA11-AS expression was notably reduced in GC xenograft tumors infected with sh-HOXA11-AS lentiviruses (Figure 7C). And, increased miR-148a expression (Figure 7D) and reduced WNT1and β-catenin expression (Figure 7E) was observed in HOXA11-AS-depleted GC xenograft tumors. MMP-2 and MMP-9, two major members of matrix metalloproteinase (MMP) family, can lead to tumor metastasis by degrading collagen in the extracellular matrix (ECM) (16, 17). Our study further demonstrated that HOXA11-AS deficiency triggered the remarkable downregulation of MMP-2 and MMP-9 levels in GC xenograft tumors (Figure 7E). In a word, these data indicated that knockdown of HOXA11-AS suppressed GC xenograft tumor growth and metastasis via regulating miR-148a/WNT1/β-catenin pathway in vivo.
GC is a serious threat for human health. Till now, surgery is still the main therapeutic strategy for GC, but high recurrence rate heavily impairs the clinical outcomes after surgical resection. LncRNAs, initially thought to be transcriptional noise, are emerging as pivotal players in a variety of cancers including GC. Over the past decades, lncRNA HOXA11-AS has been found to be implicated in the initiation and progression of multiple solid tumors. For instance, HOXA11-AS overexpression accelerated cell proliferation and invasion in ovarian cancer . HOXA11-AS loss repressed cell proliferation, migration, invasion, and angiogenesis, while induced cell cycle arrest and apoptosis in non-small cell lung cancer (NSCLC) . And, Qu et al. suggested that HOXA11-AS expression was associated with advanced pathogenic status and poor prognosis of laryngeal squamous cell cancer (LSCC) patients, and HOXA11-AS depletion suppressed LSCC cell proliferation, migration and invasion . Consistent with previous studies, we observed that HOXA11-AS level was obviously elevated in GC tissues and cell lines, and associated with tumor size, lymph node metastasis, advanced tumor stages and poor survival in GC. Previous studies used two different cell lines to investigate the effects of elevation or decrease of lncRNA HOTAIR and TINCR on cancer progression [21,22]. In this text, SGC-7901 cells were selected to conduct the gain-of-function investigations and MGC-803 cells were opted for the following loss-of-function analysis due to lower HOXA11-AS expression in SGC-7901 cells and higher HOXA11-AS expression in MGC-803 cells. Our data revealed that cell migratory and invasive capacities were improved in HOXA11-AS-overexpressed SGC-7901 cells, but was reduced in HOXA11-AS-depleted MGC-803 cells, suggesting the oncogenic effects of HOXA11-AS in GC. In agreement with our outcomes, Liu et al. demonstrated that HOXA11-AS knockdown suppressed GC cell proliferation, migration and invasion in vitro and hampered GC xenograft tumor metastasis in vivo .
Emerging evidence supports that lncRNAs can function as the molecular sponges of miRNAs to sequester miRNAs from their targets, leading to the increase of target levels [24,25]. In this study, we demonstrated that HOXA11-AS served as a ceRNA of miR-148a to relieve the inhibitory effect of miR-148a on WNT1 expression in GC cells. Functional restoration experiments revealed that miR-148a overexpression curbed the elevation of cell migratory and invasive abilities induced by HOXA11-AS in GC, suggesting that HOXA11-AS conferred the malignant phenotypes of GC cells via downregulating miR-148a. In agreement with our data, the tumor-suppressive roles of miR-148a have been elucidated in several types of cancers including GC. For instance, miR-148a level was significantly reduced in GC tissues and miR-148a could regulate GC cell invasion via targeting MMP7 . Enforced expression of miR-148a hindered cell growth and invasion through targeting TGFβ2 and SMAD2 in GC .
WNT1, a member of WNT gene family, has been widely reported to be involved in the regulation of cell fate and embryonic development. And, mounting evidences elucidate that WNT1 plays central roles in oncogenesis via regulation of β-catenin-dependent signaling pathway [28,29]. For example, miR-148a weakened migratory and invasive capacities of breast cancer cells by targeting WNT1 and inactivating WNT/β-catenin signaling pathway . MiR-185 functioned as a tumor suppressor by repressing WNT1 and blockading associated WNT/β-catenin pathway in colon cancer . Moreover, a previous report pointed out that miR-501-5p induced stem cell like phenotypes of GC by activating WNT/β-catenin pathway via directly targeting WNT pathway antagonists such as DKK1, NKD1 and GSK3β .
In this study, we further demonstrated that WNT1 was a target of miR-148a and miR-148a inhibited WNT1 expression by direct interaction. β-catenin is previously identified as a key molecule of WNT/β-catenin pathway . Here, we also confirmed that β-catenin level was downregulated in miR-148a-overexpressed GC cells, but was upregulated in miR-148a-depleted GC cells. And, we did not find the evidence to support the suppose that β-catenin can be directly targeted by miR-148a. Thus, we believed that the inhibitory effect of miR-148a on β-catenin expression was realized possibly by targeting WNT1. Following study further showed that miR-148a overexpression abolished the promotive effects of HOXA11-AS on WNT1 and β-catenin expression, suggesting that HOXA11-AS activated WNT1/β-catenin signaling pathway through modulation of miR-148a/WNT1 axis.
A large number of genes, such as transcription factor 3 (TCF3), zinc finger E-box binding homeobox transcription factor 1 (ZEB1), inhibitor of differentiation 2 (ID2), and SNAI2, have been found to be associated with the malignant metastatic phenotypes of tumor cells [34-37]. HOXA11-AS/miR-148a/WNT1/β-catenin reported in our study is one of multitudinous HOXA11-AS-involved regulatory mechanisms that are correlated with cell invasion and migration in GC. In the following study, we intend to further explore whether HOXA11-AS can regulate GC initiation and progression by other signaling pathways.
In conclusion, our data indicated the correlation of HOXA11-AS expression and clinicopathological parameters of patients with GC. And, HOXA11-AS accelerated cell migration and invasion via modulation of miR-148a/WNT1/β-catenin pathway. Our findings uncovered a novel regulatory mechanism for GC development and provided a potential therapeutic target for GC.
TG and XY designed the study. DFLcollected the data. TG, XY and SHP carried out the statistical analyses. TG, XY and AMX prepared the figures. All authors wrote the manuscript. All authors read and approved the final manuscript
Our study was performed with the approval of the Research Ethics Committee of The First Affiliated Hospital of Anhui Medical University and all participants signed written informed consent prior this research.
Subscribe to our articles alerts and stay tuned.
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."